Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
9.86
-0.07 (-0.70%)
Mar 19, 2026, 1:23 PM EDT - Market open
Relay Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Relay Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $16.14, which forecasts a 63.69% increase in the stock price over the next year. The lowest target is $10 and the highest is $22.
Price Target: $16.14 (+63.69%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Relay Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 6 | 6 | 6 | 4 |
| Buy | 4 | 2 | 2 | 2 | 2 | 3 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 9 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $15 → $17 | Buy | Maintains | $15 → $17 | +72.41% | Mar 17, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $15 → $17 | Buy | Maintains | $15 → $17 | +72.41% | Mar 17, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $15 → $22 | Strong Buy | Maintains | $15 → $22 | +123.12% | Mar 13, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $13 → $15 | Buy | Maintains | $13 → $15 | +52.13% | Feb 27, 2026 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $14 | Hold → Buy | Upgrades | $14 | +41.99% | Jan 26, 2026 |
Financial Forecast
Revenue This Year
4.10M
from 15.36M
Decreased by -73.28%
Revenue Next Year
20.35M
from 4.10M
Increased by 396.00%
EPS This Year
-1.63
from -1.61
EPS Next Year
-1.56
from -1.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 15.8M | 75.0M | |||
| Avg | 4.1M | 20.4M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.6% | 1,727.2% | |||
| Avg | -73.3% | 396.0% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.32 | -1.26 | |||
| Avg | -1.63 | -1.56 | |||
| Low | -2.24 | -2.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.